DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

DNA following subchronic doxorubicin administration.
Biochem Biophys Acta, 1999, 1411:201–205.
Sharma S, Gong P, Temple B, et al. Molecular dynamic simulations
of cisplatin- and oxaliplatin-d(GG) intrastrand cross-links
reveal differences in their conformational dynamics. J Mol Biol,
2007, 373:1123–1140.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy
plus a monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. N Engl J Med, 2001,
344:783–792.
Soares DG, Escargueil AE, Poindessous V, et al. Replication and
homologous recombination repair regulate DNA double-strand
break formation by the antitumor alkylator ecteinascidin 743.
Proc Natl Acad Sci U S A, 2007, 104:13062–13067.
Sobell HM. The stereochemistry of actinomycin binding to DNA
and its implications in molecular biology. Prog Nucleic Acid
Res Mol Biol, 1973, 13:153–190.
Soignet SL, Maslak P, Wang ZG, et al. Complete remission after
treatment of acute promyelocytic leukemia with arsenic trioxide.
N Engl J Med, 1998, 339:1341–1348.
Sonneveld P, Schultz FW, Nooter K, Hahlen K. Pharmacokinetics
of methotrexate and 7-hydroxy-methotrexate in plasma and
bone marrow of children receiving low-dose oral methotrexate.
Cancer Chemother Pharmacol, 1986, 18:111–116.
Souliotis VL, Kaila S, Boussiotis VA, et al. Accumulation of O 6 -
methylguanine in human blood leukocyte DNA during exposure
to procarbazine and its relationships with dose and repair.
Cancer Res, 1990, 50:2759–2764.
Stevens EV, Nishizuka S, Antony S, et al. Predicting cisplatin
and trabectedin drug sensitivity in ovarian and colon cancers.
Mol Cancer Ther, 2008, 7:10–18.
Stoller RG, Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics
to predict and prevent methotrexate toxicity. N Engl
J Med, 1977, 297:630–634.
Stresemann C, Lyko F. Modes of action of the DNA methyltransferase
inhibitors azacytidine and decitabine. Int J Cancer,
2008, 123:8–13.
Sugimoto Y, Tsukahara S, Oh-hara T, et al. Decreased expression
of DNA topoisomerase I in camptothecin-resistant tumor
cell lines as determined by monoclonal antibody. Cancer Res,
1990, 50:6925–6930.
Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with
dexrazoxane for doxorubicin-containing therapy in advanced
breast cancer. J Clin Oncol, 1997, 15:1318–1332.
Synold TW, Takimoto CH, Doroshow JH, et al. Dose-escalating
and pharmacologic study of oxaliplatin in adult cancer patients
with impaired hepatic function: A National Cancer Institute
Organ Dysfunction Working Group study. Clin Cancer Res,
2007, 13:3660–3666.
Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic
acid receptor LPA1 links pulmonary fibrosis to lung injury by
mediating fibroblast recruitment and vascular leak. Nat Med,
2008, 14:45–54.
Takimoto CH, Graham MA, Lockwood G, et al. Oxaliplatin
pharmacokinetics and pharmacodynamics in adult cancer
patients with impaired renal function. Clin Cancer Res, 2007,
13:4832–4839.
Tam CS, O’Brien S, Wierda W, et al. Long-term results of the
fludarabine, cyclophosphamide, and rituximab regimen as initial
therapy of chronic lymphocytic leukemia. Blood, 2008,
112:975–980.
Tamura H, Kohchi C, Yamada R, et al. Molecular cloning of a
cDNA of a camptothecin-resistant human DNA topoisomerase
I and identification of mutation sites. Nucleic Acids Res, 1991,
19:69–75.
Tavecchio M, Simone M, Erba E, et al. Role of homologous
recombination in trabectedin-induced DNA damage. Eur J
Cancer, 2008, 44:609–618.
Teichert J, Baumann F, Chao Q, et al. Characterization of two
phase I metabolites of bendamustine in human liver microsomes
and in cancer patients treated with bendamustine hydrochloride.
Cancer Chemother Pharmacol, 2007, 59:759–770.
Tew K, Colvin M, Chabner BA. Alkylating agents. In: Chabner
BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy:
Principles and Practice, 3rd ed. Philadelphia, Lippincott
Williams & Wilkins, 2001, pp. 373–414.
Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine
for metastatic breast cancer progressing after anthracycline and
taxane treatment. J Clin Oncol, 2007, 25:5210–5217.
Tsao YP, Russo A, Nyamuswa G, et al. Interaction between replication
forks and topoisomerase I-DNA cleavable complexes:
Studies in a cell-free SV40 DNA replication system. Cancer
Res, 1993, 53:5908–5914.
Twelves CJ, Dobbs NA, Gillies HC, et al. Doxorubicin pharmacokinetics:
The effect of abnormal liver biochemistry tests.
Cancer Chemother Pharmacol, 1998, 42:229–234.
Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic
dysfunction due to liver metastases on the pharmacokinetics of
capecitabine and its metabolites. Clin Cancer Res, 1999,
5:1696–1702.
Twentyman PR. Bleomycin: Mode of action with particular reference
to the cell cycle. Pharmacol Ther, 1983, 23:417–441.
Van Ark-Otte J, Kedde MA, van der Vijgh WJ, et al.
Determinants of CPT-11 and SN-38 activities in human lung
cancer cells. Br J Cancer, 1998, 77:2171–2176.
Van Triest B, Pinedo HM, Blaauwgeers JL, et al. Prognostic role
of thymidylate synthase, thymidine phosphorylase/plateletderived
endothelial cell growth factor, and proliferation markers
in colorectal cancer. Clin Cancer Res, 2000, 6:1063–1072.
Vassal G, Challine D, Koscielny S, et al. Chronopharmacology of
high-dose busulfan in children. Cancer Res, 1993, 53:1534–1537.
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III
study of pemetrexed in combination with cisplatin versus cisplatin
alone in patients with malignant pleural mesothelioma.
J Clin Oncol, 2003, 21:2636–2644.
Wall SM, Johansen MJ, Molony DA, et al. Effective clearance of
methotrexate using high-flux hemodialysis membranes. Am J
Kidney Dis, 1996, 28:846–854.
Walter N, Collard HR, King TE Jr. Current perspectives on the
treatment of idiopathic pulmonary fibrosis. Proc Am Thorac
Soc, 2006, 3:330–338.
Wang J, Lohman GJS, Stubbe J. Enhanced subunit interactions
with gemcitabine-5′-diphosphate inhibit ribonucleotide reductase.
Proc Natl Acad Sci U S A, 2007, 104:14324–14329.
Wang ZM, Chen ZP, Xu ZY, et al. In vitro evidence for homologous
recombinational repair in resistance to melphalan. J Natl
Cancer Inst, 2001, 93:1473–1478.
Wang ZY, Chen Z. Acute promyelocytic leukemia: From highly
fatal to highly curable. Blood, 2008, 111:2505–2515.
Washtein WL. Thymidylate synthetase levels as a factor in 5-
fluorodeoxyuridine and methotrexate cytotoxicity in gastrointestinal
tumor cells. Mol Pharmacol, 1982, 21: 723–728.
1729
CHAPTER 61
CYTOTOXIC AGENTS